Nanopeutics signs exclusive technology agreement with HemCon Medical Technologies, Inc. for Military market
-- development of a range of specialist chitosan based nanofibre wound care technologies and products --
Thursday, 18th January 2007; Portland, Oregon & Liberec Czech Republic
Nanopeutics s.r.o. the joint venture company of Alltracel Pharmaceuticals plc (AP.L) and Elmarco s.r.o. which is dedicated to the commercialisation of Nanospider™ technology for the global woundcare market, has signed an exclusive technology and product concept development agreement with HemCon Medical Technologies, Inc. the haemorrhage control market leaders in military markets.
The successful conclusion to the development work, which has already commenced following successful initial product tests, is expected to lead to a licence and supply agreement for a range of chitosan based Nanospider™ woundcare technologies and products for exclusively military market usage.
John W. Morgan, President & CEO HemCon Medical Technologies commented:
“As the leader and key innovator in hemorrhage control in the military market, HemCon is dedicated to a significant R&D effort on our platform technology of advanced chitosan materials. Initial product tests on Nanospider™ spun chitosan are very encouraging and we are excited to be working with the Nanopeutics teams on the development of this breakthrough technology for the specialist military markets”
Nanopeutics CEO Camillus Glover commented:
“This agreement with HemCon for the military market is the second significant collaboration for Nanopeutics’ advanced woundcare technology. HemCon is highly regarded for innovation with unrivalled experience working with chitosan in the woundcare area and we are delighted to be teaming with them on this exciting market opportunity. ”
End
For Further Information Contact:
Dublin: Karen Muldowney
Nanopeutics: +353 1 235 2162
press@nanopeutics.com
Liberec: Pavel Novotny
Nanopeutics: +420 489 209 127
press@nanopeutics.net
Notes to Editors follow:
HemCon Medical Technologies, Inc. (“HemCon”) (www.hemcon.com) founded in 2001, develops, manufactures, and markets innovative technologies to control bleeding and infection resulting from trauma or surgery.
HemCon products are designed for use by military and civilian first responders as well as medical professionals in hospital, dental and clinical settings where rapid control of bleeding is of critical importance.
The HemCon® Bandage was developed in collaboration with the Oregon Medical Laser Center and Providence St. Vincent’s Hospital.
HemCon’s manufacturing and corporate headquarters are located in Portland, Oregon.
Nanopeutics™ s.r.o. (“Nanopeutics”) (www.nanopeutics.net) is the specialist Alltracel Pharmaceuticals (AIM: AP.L) (www.alltracel.com) subsidiary formed as part of a joint venture with Elmarco s.r.o. (www.elmarco.com) dedicated to the commercialisation of Nanospider™ technology for the global professional and consumer woundcare markets.
Nanopeutics, headquartered in Liberec in the Czech Republic and operating internationally, has been licensed and/or assigned the relevant woundcare and Nanospider™ intellectual property and patents
Nanospider™ is the novel patented process for spinning polymers into nano-scale fibres for a range of industrial, chemical, micro-electronic and bio-medical applications. The Nanospider™ technology has been recognised internationally as a major breakthrough in the mass production of nanofibre materials.
Nanospider™ and Nanopeutics™ are trademarks controlled by Nanopeutics s.r.o
|
